Pharmacological intervention to restore connectivity deficits of neuronal networks derived from ASD patient iPSC with a TSC2 mutation by Alsaqati, Mouhamed et al.
 1 
 
Pharmacological intervention to restore connectivity deficits of neuronal networks 1 
derived from ASD patient iPSC with a TSC2 mutation 2 
 3 
Mouhamed Alsaqati, PhD, Vivi M Heine, PhD and Adrian J Harwood, PhD* 4 
 5 
 6 
 7 
 8 
*Corresponding author 9 
Adrian J Harwood, PhD 10 
Neuroscience and Mental Health Research Institute, 11 
Haydn Ellis Building, Cardiff, CF24 4HQ 12 
harwoodaj@cardiff.ac.uk 13 
+44(0) 29 2068 8492  14 
ManXscripW COick heUe WR acceVV/dRZQORad;MaQXVcUiSW;TSC VecRQd
UeYiViRQ 2.dRc[Click here to YieZ linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
 
Abstract 1 
Background  2 
Tuberous sclerosis complex (TSC) is a rare genetic multisystemic disorder resulting from 3 
autosomal dominant mutations in the TSC1 or TSC2 genes. It is characterised by 4 
hyperactivation of the mechanistic target of rapamycin complex 1 (mTORC1) pathway and 5 
has severe neurodevelopmental and neurological components including autism, intellectual 6 
disability and epilepsy. In human and rodent models, loss of the TSC proteins causes neuronal 7 
hyperexcitability and synaptic dysfunction, although the consequences of these changes for 8 
the developing central nervous system is currently unclear. 9 
Methods 10 
Here we apply Multi-electrode array (MEA)-based assays to study the effects of TSC2 loss on 11 
neuronal network activity using Autism Spectrum Disorder (ASD) patient-derived iPSCs. We 12 
examine both temporal synchronisation of neuronal bursting, and spatial connectivity between 13 
electrodes across the network.  14 
Results  15 
We find that ASD patient-derived neurons with a functional loss of TSC2, in addition to 16 
possessing neuronal hyperactivity, develop a dysfunctional neuronal network with reduced 17 
synchronisation of neuronal bursting and lower spatial connectivity. These deficits of network 18 
function are associated with elevated expression of genes for inhibitory GABA signalling and 19 
glutamate signalling, indicating a potential abnormality of synaptic inhibitory-excitatory 20 
signalling. mTORC1 activity functions within a homeostatic triad of protein kinases, mTOR, 21 
AMP-dependent protein Kinase 1 (AMPK), and Unc-51 like Autophagy Activating Kinase 1 22 
(ULK1) that orchestrate the interplay of anabolic cell growth and catabolic autophagy while 23 
balancing energy and nutrient homeostasis. The mTOR inhibitor rapamycin suppresses 24 
neuronal hyperactivity, but does not increase synchronised network activity, whereas 25 
activation of AMPK restores some aspects of network activity. In contrast, the ULK1 activator, 26 
LYN-1604 increases the network behaviour, shortens the network burst lengths, and reduces 27 
the number of uncorrelated spikes. 28 
Limitations 29 
Although a robust and consistent phenotype is observed across multiple independent iPSC 30 
cultures, the results are based on one patient. There may be more subtle differences between 31 
patients with different TSC2 mutations or differences of polygenic background within their 32 
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genomes. This may affect the severity of the network deficit or the pharmacological response 1 
between TSC2 patients. 2 
Conclusions 3 
Our observations suggest that there is a reduction in the network connectivity of the in vitro 4 
neuronal network associated with ASD patients with TSC2 mutation, which may arise via an 5 
excitatory/inhibitory imbalance due to increased GABA-signalling at inhibitory synapses. This 6 
abnormality can be effectively suppressed via activation of ULK1. 7 
  8 
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Introduction 1 
Tuberous sclerosis complex (TSC) is a developmental genetic disorder characterised by the 2 
widespread progression of benign tumours in multiple organs. It affects approximately 1:6000 3 
individuals and is caused by mutations in either TSC1 or TSC2 [1]. The most common 4 
neurological symptoms associated with TSC are: epilepsy which occurs in 80-90% of patients 5 
and is often unmanageable; autism spectrum disorder (ASD) or intellectual disability, which 6 
occurs in approximately 50% [1]. The TSC1 and TSC2 proteins form a heterodimer complex 7 
that binds to a third subunit (TBC1D7) to form the TSC complex. This complex acts as a 8 
GTPase activating protein (GAP). TSC2 protein consists of the GAP domain and most 9 
phosphorylation sites, whereas the TSC1 acts as a stabiliser of the complex and prevents 10 
TSC2 degradation [2]. Both TSC1 and TSC2 are involved in the stability of the complex and 11 
for that reason patients with either gene mutation present with similar clinical phenotypes. The 12 
main role of the TSC complex is the regulation of mechanistic target of rapamycin (mTOR) 13 
that exists as two functionally distinct complexes termed, mTOR complex 1 and 2 (mTORC1 14 
and mTORC2)  [3]. The mTORC1 pathway plays key roles in multiple cellular processes; such 15 
as cell growth and division; autophagy, and transcription [4, 5]. Loss of TSC1 or TSC2 function 16 
activates mTOR signalling, which results in an mTORC1‐dependent increase of ribosomal 17 
protein S6 (rpS6), rpS6 kinase 1 (S6K1) eukaryotic initiating factor 4E-binding protein 1 (4E‐18 
BP1) phosphorylation [6, 7]. Aberrant mTORC1 signalling has been identified in cancer 19 
progression, diabetes and aging, and is involved in increasing cell growth and proliferation [2, 20 
8]. 21 
Reports demonstrate that hyperactivation of mTORC1 signalling in neurons is associated with 22 
aberrant axonal and dendritic connectivity, enlarged soma size, increased cellular stress, 23 
reduced myelination, synaptic dysfunction and neuronal hyperexcitability [9-12]. In animal 24 
models, treatment with mTORC1 inhibitor, rapamycin recovered the behavioural deficits 25 
including learning, memory, and autistic‐like features and the neuronal hyperexcitability [13-26 
15]. In human models, rapamycin reversed neuronal hyperexcitability and improved recall 27 
memory in patients with angiomyolipomas associated with TSC [16-18]. However, other 28 
neuropsychological measures including executive functions and recognition memory showed 29 
reduction in some participants [18]. Additionally, rapamycin did not ameliorate neurocognitive 30 
dysfunction or behavioural issues in children with TSC [18].  31 
An alternative to direct inhibition of mTOR is to target mTORC1 via AMP-activated protein 32 
kinase (AMPK) and Unc-51 Like Autophagy Activating Kinase 1 (ULK1), which both inhibit 33 
mTORC1 by phosphorylation of its Raptor subunit [19, 20]. Furthermore, AMPK targets 34 
mTORC1 indirectly by phosphorylation and activation of ULK1, and activation of TSC1/TSC2 35 
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[21, 22]. However, mTORC1 activity inhibits ULK-1 [19, 20], therefore in TSC2 deficit cells 1 
ULK-1 activity may experience higher levels of inhibition [23, 24]. In principle, activation of 2 
either AMPK or ULK1 should alleviate the effect of hyperactivation of mTORC1 in TSC2 deficit 3 
cells, however the outcome of drug treatments that target AMPK or ULK1 will be dependent 4 
on the balance of activity of each kinase within the target cells.  5 
In this study, we demonstrate abnormal neuronal network behaviour in patient-derived 6 
neurons with a TSC2 gene mutation and use a novel pharmacological approach to suppress 7 
this neuronal dysfunction. We show that although the previously observed neuronal 8 
hyperexcitability of TSC patient-derived neurons was suppressed by rapamycin, aberrant 9 
neuronal network behaviour could not be rescued. Of the two protein kinases, AMPK and 10 
ULK1, only ULK1 activation reduced all aspects of the patient cell phenotype. This strategy of 11 
suppressing the disease state could be further developed as a new treatment for TSC patients. 12 
 13 
Materials and methods  14 
iPSCs and Neuronal Cultures 15 
TSC patient iPSC clone hVS-417 (P2C) from patient2 was obtained from the Coriell 16 
Biorepository (all teenage donors), and two independent iPSC clones hVS-88 (C1) (infant) 17 
and hVS-228 (C2) (teenage) were obtained from anonymous control donors. iPSC 18 
reprogramming was done based on polycistronic construct with OCT3/4, c-MYC, SOX2, 19 
and KLF4 [25]. The iPSC line (patient 2: line 417, MD5, P2) selected for this study was derived 20 
from a patient with mental retardation and seizures along with other TSC-related 21 
abnormalities. All cells were cultured in Essential 8 medium (Gibco) on Geltrex LDEV-free 22 
(Gibco). Generation of in-direct contact iPSC-neuronal cultures for the two independent 23 
control (1 batch of differentiations each) and one TSC2 patient line (2 batches of 24 
differentiations) was performed as described earlier [26] with slight modifications. Briefly, high-25 
density hiPSC cultures were passaged onto Geltrex (GIBCO)-coated plates. When hiPSC 26 
cultures reached confluence, they were neural induced with Noggin (500 ng/ ml; Peprotech), 27 
and SB431542 (10 ȝM; Stegment and Selleck chemicals). Neural rosettes were picked 28 
manually and cultured in neural maintenance medium (NMM) with FGF2 (20 ng/ ml) and EGF 29 
(20 ng/ ml; Peprotech) on PLO (20 ȝg/ ml)/mouse laminin (20 ȝg/ ml; both from Sigma) pre-30 
coated plates. Neuronal cultures with a density of 62.5 K/2.0 cm2 were maintained in the 31 
medium contained neurobasal composition with brain-derived neurotrophic factor (BDNF) 32 
(20 ng/mL; Peprotech) and cAMP (1 ȝM; Sigma). At day 45 of differentiation some cultures 33 
were treated with 10nM rapamycin for the remainder of the cultures. To 34 
promote maturation neurons were treated with CultureOne™ Supplement (Cat No. A3320201) 35 
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at day50 of differentiation for two days. At day 60 of differentiation, TSC2 patient and control 1 
neurons were plated on the MEAs. MEA analyses were performed on the combined results 2 
for the two controls and patient cultures since the variance within the control and the TSC2 3 
groups were low. 4 
 Multiple Electrode Arrays (MEAs) 5 
All experiments were performed using CytoView MEA 24-well plates (M384-tMEA-24W, 4X4 6 
electrode grid). MEAs were first pre-treated with 0.01% polyethylenimine (Sigma) and 7 
incubated for 1 hour at 37°C. Day 60 neurons were plated as high density drop cultures (5,000 8 
cells/µL) containing 10µg/ml laminin. After 1 hour, conditioned medium was added into each 9 
MEA and after 24 hours 0.5ml of fresh BrainPhys media was added to each array. MEA 10 
cultures were maintained in 1:1 fresh to normal human astrocytes (NHA) condition BrainPhys 11 
media replaced every 3-4 days. Electrophysiological activity was recorded every 10 days using 12 
hardware (Maestro Pro complete with Maestro 768channel amplifier) and software (AxIS 13 
1.5.2) from Axion Biosystems (Axion Biosystems Inc., Atlanta, GA). Channels were sampled 14 
simultaneously with a gain of 1000× and a sampling rate of 12.5 kHz/channel. During the 15 
recording, the temperature was maintained constant at 37°C. All active electrodes were 16 
included in the analysis. Before every recording all recorded wells are rigorously quality 17 
controlled to check that the cells are not clumped or lifted off, and they also have to cover at 18 
least 80% of the electrodes. Any well that does not meet these criteria will be excluded from 19 
the analysis. 20 
For drug treatment, LYN-1604 were purchased from Cambridge Bioscience (Cambridge, UK), 21 
rapamycin were purchased from Sigma-Aldrich (St. Louis, MO, USA), CNQX, APV, kainic acid 22 
and bicuculline from R&D System (R&D System Inc., Minneapolis, MN, USA), ACIAR and 23 
methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM) were purchased from 24 
Tocris (Bio-Techne Ltd.). Stock concentrations were diluted as required in 1ௗmL 1:1 25 
BrainPhys:BrainPhys ACM. Medium containing diluted drugs were added to MEAs and 26 
subsequently incubated for 10ௗmins at 37ௗ°C in a standard 5% CO2 incubator environment 27 
unless otherwise stated. After recordings, medium was removed from MEAs and cultures were 28 
washed 3 times with PBS. 1ௗml of fresh medium was then added, and cultures were incubated 29 
for 10ௗminutes as before. This medium was then removed and replaced with fresh medium 30 
and recorded again. 31 
A Butterworth band-pass filter (with a high-pass cut-off of 200 Hz and low-pass cut-off of 32 
3000Hz) was applied along with a variable threshold spike detector set at 5.5× standard 33 
deviation on each channel. Offline analysis was achieved with custom scripts written in 34 
MATLAB (available on request). Briefly, spikes were detected from filtered data using an 35 
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automatic threshold-based method set at -5.5 x ı, where ı is an estimate of the noise of each 1 
electrode based upon the median absolute deviation 1. Spike timestamps were analysed to 2 
provide statistics on the general excitability of cultures. Neuronal bursting was detected based 3 
on three parameters: inter-burst period longer than 200ms, more than 3 spikes in each burst 4 
and a maximum inter-spike (intra-burst) interval of 300 milliseconds. Network activity was 5 
illustrated by creating array–wide spike detection rate (ASDR) plots with a bin width of 200 6 
ms. Heat map for spatially correlated neurons on the MEAs were generated with MATLAB 7 
imagesc function using in-house scripts. In the heat maps, a dark red-dark blue colour scale 8 
was used whereby shades of red and blue represented higher and lower correlations, 9 
respectively, for control or TSC2 neurons plated on the 16 electrode-grid. 10 
RNA extraction and quantitative (q)PCR 11 
Cells were lysed with QIAzol Lysis Reagent (Life Technologies) and stored at -20 °C. Total 12 
RNA was extracted from hiPSCs-derived TSC and control neuron lysates using the miRNeasy 13 
mini kit (reference 217004, Qiagen, Germany). For each sample, 1µg of total RNA was reverse 14 
transcribed using the miScript II RT Kit (Qiagen). For qPCR analysis QuantiTect SYBR Green 15 
PCR kit (Qiagen, Germany) was employed and samples were run on a StepOnePlus™ Real-16 
Time PCR System (Applied Biosystems) following the manufacturer¶s instructions. All 17 
reactions were performed in triplicate for each sample. The relative expression levels of the 18 
miRNAs and other genes was calculated using the 2-ǻǻCT method [27] and the data were 19 
normalized to GAPDH and Colrf43. The primer sequences for all genes examined in the 20 
current study are listed in Table S1. 21 
Statistical analysis 22 
Prism 8.0 (GraphPad Software) was used for the statistical analysis. Data shown are the 23 
meanௗ±ௗs.e.m. with Pௗ<ௗ0.05 considered statistically significant. Two-tailed unpaired/paired t-24 
tests were used for comparisons between two groups. Data distribution was assumed to be 25 
normal, but this was not formally tested. 26 
 27 
Results 28 
TSC2 patient iPSCs-derived neurons exhibit higher neuronal excitability but decreased 29 
synchronicity 30 
In previous work, we reported enhanced neuronal excitability of iPSCs derived from ASD with 31 
TSC1 or TSC2 mutations [17]. In these experiments, mature neurons exhibited increased 32 
spontaneous calcium influx frequencies and an increased firing rate of TSC patient-derived 33 
neurons plated on MEAs as compared to control neurons [17]. In the current study, we have 34 
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investigated the synchronisation and connectivity of neuronal network activity of two 1 
independent control lines and one patient that was lacking functional TSC2, possessing a 2 
single nucleotide duplication (1563dupA) leading to a frameshift mutation H522T [17].  Several 3 
iPSC clones were obtained from each patient and control fibroblast line and verified by 4 
sequencing and characterised by immunostaining as previously shown [17].  5 
Control and patient iPSCs were differentiated into functional neurons, and at ~day 60 of 6 
differentiation neurons were plated on the MEA plate to record their activities. Spike detection 7 
from filtered raw voltage recording were generated from each electrode via the threshold-8 
based method of QuianQuiroga and colleagues [28] and following quality control spikes were 9 
time-stamped for subsequent analysis. As previously reported, spontaneous activity of 10 
cultures on MEAs differed between control and TSC2  mutated patient neurons (Fig. 1A, B) 11 
with increased spontaneous firing rates and higher total numbers of single unit bursts in TSC2 12 
neurons, with 0.9 ± 0.2 Hz, 273.1 ± 68.81 bursts, respectively compared to the control values 13 
of 0.16 Hz ± 0.07 Hz, 57.67 ± 46.76 bursts, respectively (p < 0.01, p < 0.05, unpaired t-test, 14 
Fig. 1C).  15 
After 20 days on MEAs, synchronised bursting emerges, where multiple electrodes across the 16 
array simultaneously detect burst firing. Control neuronal cultures develop a regular pattern of 17 
synchronised bursts (SBs) separated by intervals of similar length, consistent with that 18 
previously reported [29] (Fig. 1A, B, S1). In TSC2 mutated patient neurons, there was a 19 
significant reduction in SB frequency (Fig. 1A, B). For example, at 40DPP (days post plating) 20 
the number of SBs was significantly lower in TSC2 neurons, 4.5 ± 1.55 SBs as compared to 21 
control neurons, 22.67 ± 4.4 SBs (p < 0.01, unpaired t-test, Fig. 1D). Consistent with elevated 22 
general spontaneous activity in TSC2 neurons, the firing rate within the TSC2 SBs was higher; 23 
for example, at 40DPP the SB firing rate in TSC2 neurons was 282.3 ± 77.04 Hz as compared 24 
to 13.67 ± 2.33 Hz in control neurons (p < 0.05, unpaired t-test, Fig. 1D). This suggests that 25 
although a higher intrinsic neuronal activity is present in TSC2 neurons, it is not reflected in 26 
increased synchronised activity within the neuronal network, and in fact there exists a 27 
previously undetected deficit in network behaviour of the patient neurons. 28 
To probe further we investigated how the pattern of neuronal firing differed between control 29 
and TSC2 neurons. As would be predicted in the case of increased neuronal activity but 30 
decreased synchronisation, the percentage of firing spikes occurring outside SBs was 31 
significantly higher in TSC2 neurons (78.44 ± 8.5% in TSC2 neurons as compared to 38.5 ± 32 
9.8% in control neurons (p < 0.05, unpaired t-test, Fig. 1E). However, when SBs did occur in 33 
the TSC2 neurons, they persisted for a longer period compared to those in control neurons; 34 
approx. 2.9-fold longer at 40 DPP than those in the control (1.25 ± 0.13 s, 3.65 ± 0.54 s (p < 35 
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0.01, unpaired t-test), (Fig. 1F). This is accompanied by a substantial increase, approx. 5.8-1 
fold, in the time interval between SB for TSC2 neurons compared to controls (151.5 ± 50.21 v 2 
26.67 ± 4.37 s at 40DPP, p = 0.09, unpaired t-test), (Fig. 1F). Due to higher variation in SB 3 
interval observed forTSC2 neurons, the increased SB interval did not reach a p<0.05 4 
threshold, conventionally considered as statistically significant. To assess the increased 5 
variation with the TSC2 dataset in comparison to the control, we plotted the range of SB 6 
interval lengths for both control and TSC2 neurons (Fig. 1G). SBs in control cells exhibited a 7 
regular defined pattern with intervals that are tightly clustered around the mean interval length, 8 
in contrast the distribution of the interval times in TSC2 neurons were widely dispersed with a 9 
range approx. 5-fold greater than control (Fig. 1G). Combined these data indicate that 10 
although the SBs of TSC2 neurons have more persistent and higher firing rates, their 11 
spontaneous frequency is significantly reduced and a disorganised. This pattern is well 12 
illustrated in Fig. 1B. 13 
This loss of synchronicity seen in the TSC2 neuronal networks is suggestive of a reduced 14 
connectivity between groups of neurons. To pursue this observation, we interrogated how the 15 
neuronal spatial connectivity may differ between the control and TSC2 neurons plated on 16 
MEAs by plotting correlation matrices between all electrodes in the MEA. In control neurons, 17 
we observed a high firing correlation between the majority of the electrodes in the cultures, 18 
represented as red and dark red pixels in Fig. 1H, indicative of high level of neuronal 19 
connectivity. The firing correlation is substantially reduced for TSC2 plated neurons, showing 20 
a loss of neuronal connectivity.  21 
Pharmacological profiling of TSC2 patient-derived neuronal networks 22 
To establish whether the SB firing patterns observed in TSC2 neurons arise due to changes 23 
in synaptic activity as previously reported in our control neurons [29], we probed our cultures 24 
with agents that modulate glutamate or GABA signalling. The agents were applied after 25 
50DPP when SBs patterns had fully established. In agreement with what we found previously 26 
in control neurons inhibition of glutamate signalling via an AMPA receptor antagonist (CNQX) 27 
or an NMDA receptor antagonist (APV) lead to a complete abolition of the SB in TSC2 cultures 28 
(Fig. S2). Previously, it has been reported that the glutamate mimic, kainic acid (KA) increased 29 
the number of SBs [30], we found that any increase in control or TSC2 neurons did not reach 30 
statistical significance (Fig. 2A, 2B). Probing TSC2 or control cultures with bicuculline or 31 
DMCM (6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate methyl ester), drugs that 32 
antagonise GABA receptors [31] increased the number of SBs (Fig. 2A, 2B). As in all of the 33 
previous cases, the patterns of the SBs rapidly recovered after washing out the drug (data not 34 
shown). Taken together, these findings indicate that consistent with observations in control 35 
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iPSCs-derived neurons, the SB patterns detected in TSC2 neurons arise via synaptic activity 1 
and that AMPA, NMDA and GABA signallings are all required for their neuronal network 2 
activity. 3 
TSC2 patient iPSC-derived neurons show an excitatory/inhibitory synaptic marker 4 
imbalance  5 
As the SB firing patterns in TSC2 neurons are dependent on synaptic activity, we interrogated 6 
whether the abnormal network phenotype observed in TSC2 neurons correlated with a 7 
potential excitatory/inhibitory imbalance. We used transcription analysis to probe possible 8 
modes of change in 1) excitatory-inhibitory cell ratio, 2) synaptic gene expression and 3) 9 
mediators of glutamate-GABA signalling. At the end of the MEA recording period ~60DPP, 10 
mRNA levels in TSC2 and control neuron cultures were quantified by qRT-PCR (Table1, Fig. 11 
3, Fig S3).  12 
Expression of cell and regional specific markers for GABAergic cells, DLX1, DLX2, LHX6 and 13 
VGAT was used to probe the proportion of inhibitory neuron cells. In TSC2 cultures elevated 14 
GABA signalling would be expected to suppress SB formation and frequency. There was no 15 
significant expression change of these cell markers between TSC and control neurons 16 
(Table1, Fig. S3), suggesting that major changes in cell-type proportions is unlikely. 17 
Previously, we observed no significant differences in neuronal morphology or synaptic number 18 
in TSC2 patient neurons [17], and consistent with these  earlier studies there was no  19 
significant differences in expression of the postsynaptic density protein genes PSD95 and 20 
Homer1 or  the presynaptic marker synaptophysin [35] (Table1, Fig. S3). 21 
In contrast, significant differences were observed in expression of genes encoding enzymes 22 
and receptor proteins associated with glutamate-GABA signalling. GAD1 and GAD2, which 23 
encode the glutamic acid decarboxylases GAD67 and GAD65 [32] showed a statistically 24 
signi¿cant increase of approximately 5- and 20-fold changes, respectively in TSC2 neurons 25 
as compared to the controls (Table 1, Fig. 3A,B), (p < 0.05, p < 0.01, unpaired t-test). Likewise, 26 
expression of the postsynaptic GABAA receptor subunits α1, ȕ2 and Ȗ1 (GABAĮ2, GABAȕ1 27 
and GABAȖ1) were also elevated by 6-, 4- and 4-fold respectively in TSC2 neurons (Table-1, 28 
Fig. 3D-F), (p < 0.05, p < 0.001, unpaired t-test). In addition, expression of the glutamate 29 
receptor genes GRIN1, GRIN3A, and GRIA1 [33,34] and the presynaptic vesicular glutamate 30 
transporter VGLUT2, also showed a clear increase (Table 1, Fig. S3), (p < 0.05, p < 0.01, 31 
unpaired t-test). GRIN2A and GRIN2B genes had no significant change, and VGLUT1 was 32 
very strongly decreased, although its mRNA abundance is relatively low (~0.05) even in 33 
control neurons. These results are indicative of disruption of both GABA and glutamate 34 
signalling. Elevation of glutamate signalling could explain the neuronal hyperexcitability of 35 
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TSC2 model, while increased GABA signalling would be expected to suppress synchronised 1 
neuronal network behaviour [29].  2 
 3 
Chronic inhibition of mTORC1 pathway has no effect on the neuronal network 4 
behaviour in TSC2 patient neurons 5 
As loss of TSC2 increases mTORC1 activity, we interrogated whether longer-term inhibition 6 
of mTORC1 by rapamycin may rescue the neuronal network defects phenotype detected in 7 
TSC2 neurons. Control neurons and TSC2 neurons were treated with 10nM rapamycin from 8 
day 45 of differentiation, and neuronal activity of control and TSC2 mutant cells was examined 9 
at day 60 on MEAs (Fig. 4A,B). As seen previously, there was a significant decrease of 10 
neuronal hyperactivity in the basal neuronal activity (spike firing rate and total number of 11 
bursts) in TSC2-derived neuronal cultures, reaching a comparable level seen in the control 12 
firing rate, i.e. a decrease from 0.52 ± 0.09 Hz to 0.13 ± 0.02 in the presence of rapamycin, p 13 
< 0.05, unpaired t-test. However, there was no significant alteration in the overall neuronal 14 
activity or synchronicity in TSC2 patient-derived neurons, or even those of the control, with 15 
rapamycin (Fig. 4B). Given that chronic inhibition of the mTORC1 pathway did not increase 16 
the number of SBs, we tested whether short-term treatment with rapamycin may have an 17 
effect. TSC2 neurons were treated with rapamycin for 24h and then the neuronal network 18 
activity was recorded. Similar to that see in TSC2 neurons chronically treated with rapamycin, 19 
short-term rapamycin treatment decreased the basal excitability of TSC2 neurons, but again 20 
it had no effect on the SB number, SB length or percentage of spikes outside SB, although we 21 
did observe a small change in the mean interval between SB (Fig. S4). In conclusion, neither 22 
long- nor short-term rapamycin treatment had a major effect on the abnormal network pattern 23 
seen for TSC2 neurons. 24 
Suppression of mTORC1 via ULK1 enhances the neuronal synchronicity in TSC2 25 
patient-derived neuronal networks 26 
In many cell types, rapamycin is reported as being a poor inhibitor of mTORC1 due to 27 
incomplete allosteric inhibition [36]. However, TORC1 activity is also inhibited by the action of 28 
the two kinases AMPK and ULK1 (Fig. 5A). TSC2 cultures were probed with AICAR, an AMPK 29 
activator, for 24h and found to decreaseTSC2 neuronal excitability (Fig. 5B,D). Unlike 30 
rapamycin, AICAR significantly increased the number of SBs and SB length and decreased 31 
the SB firing rate in TSC2 neurons (Fig. 5Db, 5Dc). However, it did not alter the SB interval 32 
(Fig. 5Dc) or decrease the number of firing spikes outside the SBs (Fig. 5Dd). In control 33 
neurons, AICAR had no effect on the neurons basal activity and in fact reduced the number 34 
of SB following 24h of treatment (Fig. S5). 35 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 12 
 
To seek a more effective reversal of  the aberrant phenotype of TSC2 neurons we investigated 1 
LYN-1604, a small molecule which is a potent and selective ULK1 activator [37, 38] and should 2 
inhibit mTORC1 through direct phosphorylation of Raptor [23, 39]. A preliminary screen of 3 
LYN-1604 showed that in control neurons it reduced expression of GABAα2 and GRIA1 with 4 
24 hours of treatment (Fig. 5C), an indication that it may target both GABA and glutamate 5 
signalling in the TSC2 patient-derived neurons.  Consistent with this possibility, MEA cultures 6 
of TSC2 patient-derived neurons treated with LYN-1604 for 24h showed a significant increase 7 
in the number of SB, comparable to that observed in control neurons (Fig. 5Db). It also reduced 8 
the SB length and interval, and significantly decreased the number of firing spikes outside the 9 
SBs (Fig. 5Dc, 5De). Whereas the effect of LYN-1604 on the number of SBs in the control 10 
neurons is yet to be determined. 11 
As AICAR and LYN-1604 both showed degrees of improvement of synchronicity in TSC2 12 
neurons, we examined whether probing the culture with any of these drugs would alter the 13 
neuronal spatial connectivity. We analysed the correlation matrices between all electrodes of 14 
the MEAs for TSC2 neurons before and after treatment with AICAR and LYN-1604. While 15 
treatment with AICAR had no detectable effect on connectivity matrices of the TSC2 neurons 16 
plated on MEAs (Fig. S5c), treatment with LYN-1604 improved the correlation between several 17 
electrodes. This effect was presented by increasing the red and dark red pixels between 18 
several electrodes in the presence of LYN-1604, an indicative of increasing the neuronal 19 
connectivity (Fig. 5E). Taken together these results show that the defective TSC2 neuronal 20 
networks may be partially restored by induction of AMPK but are substantially restored by 21 
ULK1 activation by LYN-1604. 22 
Discussion 23 
In this report we examine the abnormal neuronal network behaviour observed in TSC2 patient 24 
iPSC-derived neurons harbouring a TSC2 mutation. We find that TSC2 patient neurons exhibit 25 
hyperexcitability but a lower degree of synchronicity. We illustrate for the first time an approach 26 
to reverse the defects in TSC2 neuronal synchronicity through the activation of AMPK and 27 
ULK1, which would activate autophagy and mechanistically inhibit mTORC1 through 28 
phosphorylation of Raptor. The aberrant network behaviour of TSC2 patient-derived neurons 29 
could be explained by an excitatory/inhibitory synaptic imbalance. The higher level of genes 30 
for GABA signalling at the synapse may shift the excitatory-inhibitory balance toward inhibition 31 
and could account for the reduction in the SB frequency, the disorganisation in SB patterns 32 
and the reduction in neuronal spatial connectivity.  33 
In mouse models, loss of Tsc1 from all neurons in local cortical circuits or the hippocampus 34 
led to neuronal hyperexcitability measured by increased spontaneous neuronal activity and 35 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 13 
 
induction of a seizure-like phenotype [40, 41]. The latter phenotype was shown to be due to 1 
an imbalance in excitation and inhibition and a reduction in inhibition onto Tsc1 KO pyramidal 2 
neurons [41]. Knockout of Tsc1 in mouse neurons also showed clinical and electrographic 3 
seizures both spontaneously and under physical stimulation, and they also exhibited enlarged 4 
cortical and hippocampus neurons [42]. TSC1 KO mice presented with short spike bursts, 5 
spontaneous periods of desynchronization or frequent high-amplitude sharp waves [42]. We 6 
have previously examined the effect of losing one copy of TSC1 or 2 on neuronal morphology 7 
and excitability. We showed that TSC2-derived neurons have common neuronal defects 8 
caused by both autosomal dominant TSC1 and TSC2 mutations. We found that neuronal 9 
hyperexcitability of TSC patient-derived cells was reversed by rapamycin [17]. Subsequently, 10 
Winden et al. studied the abnormalities in the neuronal excitability resulted from TSC2 11 
mutation. They used induced expression NGN2 to generate excitatory neurons from TSC2-/+, 12 
TSC2-/- and TSC2+/+ cells [16]. While their results replicate those previously observed for TSC 13 
neuronal hyperexcitability, they did not examine the network behaviour of TSC2 mutants. In 14 
particular, Winden et al. examined only excitatory neurons generated by their induced 15 
development protocol. Here, our protocol generates a mix of excitatory and inhibitory 16 
expressing GAD65/67, and is more representative of human cortical development [29,43].  17 
Our current data is consistent with our previous findings and other reports of hyperexcitability 18 
of neurons with TSC2 loss of function mutations [16, 17], but also show a reduction of network 19 
synchrony and connectivity. Previously, Sundberg et al. found that TSC2 patient neurons 20 
exhibited reduced synaptic activity, measured by a decrease in the number of functional 21 
glutamatergic synapses in relation to controls with no effect on the glutamate receptor 22 
properties [11]. In our work, the reduced synchronicity could be due to increased GABAergic 23 
signalling in this model. The regulation of coordinated network firing by GABAergic 24 
interneurons is well documented, increased GABA activity could prevent the coordination 25 
between active and non-active periods in the culture, leading to a significant elevation in the 26 
number of spikes outside the SBs. This leads to network disorganisation, manifest as a high 27 
number of random and uncorrelated spikes. The large reduction in the number of SBs detected 28 
in the TSC2 model was associated with an increase in the burst length, a feature consistent 29 
with previous reports in both animal and human models [16, 44].  30 
Our pharmacological profiling demonstrated that consistent with that already shown in control 31 
human iPSC-derived neurons and in rodent neurons, glutamate and GABA signalling are the 32 
primary drivers for the network activity in TSC2 neurons [29]. The SBs detected in TSC2 33 
neurons were completely abolished when NMDA or AMPA receptors were inhibited. 34 
Conversely, inhibition of GABAA receptors increased the number of SBs and decreased the 35 
SB intervals. This indicates that, as for non-patient cells, in our TSC2 patient cells glutamate 36 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 14 
 
signalling is the driver of neuronal network activity while GABA signalling shapes it. 1 
Importantly, shifts in excitation or inhibition signalling causes an alteration in the excitability of 2 
local circuits lead to an impairment of information processing in the brain, which is a potential 3 
pathophysiological mechanism in several neuropsychiatric disorders including ASD, 4 
schizophrenia and epilepsies [45]. Murine Tsc1 KO hippocampal hyperexcitability was shown 5 
to result from an increase in the balance of inhibitory vs excitatory synapses [41].  6 
The hypothesis that the aberrant network behaviour observed in TSC2 neurons could be due 7 
to an increase of inhibitory/excitatory synaptic activity is supported by RNA analysis of a panel 8 
of excitatory and inhibitory synaptic markers. Whilst the genes encoding the markers for 9 
GABAergic cell types and synaptic components including synaptophysin and PSD95, did not 10 
differ from those of the control neurons [46, 47], the expression levels of presynaptic inhibitory 11 
markers and the postsynaptic GABAA receptor subunits α2, β1 and γ1 were significantly 12 
elevated in our TSC2 model. Likewise, expression of the glutamatergic markers, GRIN1, 13 
GRIA1 GRIN3A and VGLUT2 was increased, suggesting that the aberrant network behaviour 14 
detected in this model could be attributed to the excitatory/inhibitory synaptic imbalance. In 15 
line with this observation, hiPSC-derived neurons treated with GABA exhibited a significant 16 
reduction in the neuronal synchronicity [29]. Additionally, one potential mechanism of reduced 17 
synaptic activity in TSC patient-derived neurons is alteration in the level of FMRP targets [48]. 18 
In here we found that the expression of FMRP targets, GABAA receptors and GAD1 and GAD2 19 
were significantly elevated [48]. Suggesting that reduced synchrony in TSC2 patient-derived 20 
neurons could be due to dysregulation of FMRP targets which can be altered due to TSC2 21 
mutation.  22 
Interestingly, the number of SBs in TSC2 neurons did not increase following rapamycin 23 
treatment indicating that rapamycin was not able to improve the TSC2 neuronal network 24 
activity. Previous studies showed that while the involvement of rapamycin in TSC2 patients 25 
control tumour growth, its efficacy in managing neuropsychiatric-associated behaviour in 26 
TSC2 patients has remained unclear [49]. Rapamycin failed to reverse the enhanced 27 
proliferation and altered neurite outgrowth; phenotypes inherent to TSC KO NPCs [50]. As 28 
rapamycin only particularly rescues the TSC2 neuronal phenotype, having little effect on the 29 
network deficit, we targeted aberrant synchronicity and connectivity deficits with alternative 30 
approaches via upstream TSC activation or by manipulating the mTORC1 at the molecular 31 
level. We found that phosphorylation of the remaining copy of TSC2 in our model via AMPK 32 
activation increased the number of SBs. However, the number of spontaneous spikes outside 33 
of the SBs was not altered, suggesting that the culture was still disorganised and less 34 
connected. The ULK1 activator, LYN-1604, inhibits mTORC1 signalling through direct 35 
phosphorylation of Raptor [19]. We observed that ULK1 activation with LYN-1604 not only 36 
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caused an increase in the number of SBs to a level comparable to that seen in control neurons, 1 
it also significantly decreased the number of spikes outside the SBs, suggesting a more 2 
connected culture. However, LYN-1604 treatment may need further refinement as the SB 3 
length in the presence of LYN-1604 was ~4 time longer than those observed in control cells.  4 
 5 
High mTORC1 activity prevents ULK1 activation by phosphorylating ULK1 at Ser-757 and 6 
disrupts its interaction with AMPK, the TSC upstream activator [19]. ULK1 and autophagy is 7 
compromised by mTORC1 hyperactivity. However, treatment with LYN1604 would restore 8 
these defects through the reactivation of autophagy that would help restore homeostatic 9 
balance to these TSC2 cells (Fig. 5A). Interestingly, rapamycin would be more effective at 10 
activating ULK1 at a higher dose of ~50 nM but not at the dose we used in the current study 11 
(at 10 nM), which is believed to be selective at mTORC1, iC50 =20nM and carried no effect 12 
on the patterns of our control neuron firings (Fig. 4A) [51]. Furthermore, rapamycin is an 13 
allosteric inhibitor of mTORC1 that cannot completely inhibit all the mTORC1-mediated 14 
phosphorylation events in cells, as is apparent by rapamycin resistant phosphorylation sites 15 
within 4E-BP1 [36]. Autophagy induction is also resistant to rapamycin treatment in many cell 16 
types, so it is very likely that the 10 nM rapamycin treatment in this study was insufficient to 17 
induce autophagy. 18 
Limitations 19 
A limitation in our study is the number of TSC2 patients examined. Although a robust and 20 
consistent phenotype is observed across multiple independent iPSC cultures on different 21 
plates, the results are based on one patient. There may be more subtle differences between 22 
patients with different TSC2 mutations or differences of polygenic background within their 23 
genomes. This may affect the severity of the network deficit or the pharmacological response 24 
between TSC2 patients. 25 
 26 
Conclusions 27 
Taken together, we have used pharmacological approaches to rescue the aberrant neuronal 28 
network phonotype linked to TSC2 hypofunction. We have shown that disruption of mTORC1 29 
signalling via ULK1 activation as well as phosphorylation of the remaining copy of TSC2 via 30 
AMPK are able to ameliorate synaptic dysfunction in TSC2 patient-derived neurons. This 31 
approach can be used for future development of personalised therapies for these patients. 32 
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Abbreviations 1 
AMPK: AMP-dependent protein Kinase 1  2 
ASD: Autism Spectrum Disorder  3 
ASDR: array–wide spike detection rate  4 
hiPSCs: Human induced pluripotent stem cells 5 
MEA: Multi-electrode array  6 
mTORC1: mechanistic target of rapamycin complex 1 7 
qPCR: Quantitative Polymerase chain reaction 8 
SB Synchronised burst 9 
TSC: Tuberous sclerosis complex  10 
ULK1: Unc-51 like Autophagy Activating Kinase 1  11 
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Figure legends 1 
Figure 1 2 
Changes in neuronal activity of patient and control neurons recorded with multi electrode 3 
arrays (MEAs). (A) Representative voltage traces from three electrodes of the same MEA 4 
culture for control and TSC2 neurons at 40DPP (DPPௗ=ௗdays post plating). Traces from TSC2 5 
neurons show high levels of activity compared to control neurons, as expected from previous 6 
observations [17]. (B) Development of synchronised bursting across the array at 20, 30 and 7 
40DPP for control (top) and TSC2 neurons (bottom). For each time point, upper panel shows 8 
a raster plot and lower panel shows an Array-wide Synchronised Detection Rate (ASDR) plot. 9 
Vertical scale barsௗ=ௗ200 spikes per 200ௗms bin, following 5min of recording. (C) Basal 10 
excitability of control and TSC2 neurons showing average spike firing rate and number of 11 
single unit bursts detected. Changes in (D) synchronised burst (SB) activity and the number 12 
of spikes in individual SBs, (E) the spikes outside of SBs and (F) SB length and interval in 13 
control and TSC2 models. (G) Frequency distribution analysis represents the variation in the 14 
SB intervals of control neurons TSC2 neurons. (H) Connectivity Correlation matrices heat map 15 
for the control and TSC2 neurons on the MEAs, colours represent the correlation in the firing 16 
rates across the indicated electrode. Correlation matrices are calculated for 16 electrodes in 17 
control and TSC2 neurons plated on the MEAs. Values greater than zero represent positive 18 
correlation, while values below zero represent negative correlation. All plots show 19 
meansௗ±ௗSEM. *p < 0.05, **p < 0.01 following unpaired t-tests. Number of recorded wellsௗ=ௗ6 20 
for the control and 8 for TSC2 culture.  21 
 22 
Figure 2 23 
Pharmacological profiling of the network activity of TSC2 neurons. Typical synchronised burst 24 
patterns shown by raster plot (upper panel) and ASDR plots (lower patterns) for Control (A) 25 
and TSC2 (B) neurons, treated with 1 ȝM kainic acid (KA), 10 ȝM bicuculline (Bic) or 1 ȝM 26 
methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM). Plots (underneath) 27 
show meanௗ±ௗSEM of (a) spike firing rate (Hz) and (b) number of synchronised bursts (SB) for 28 
all drugs. *p < 0.05, ***p < 0.001 following paired t-tests. Number of recorded wellsௗ=ௗ3-10. 29 
 30 
Figure 3 31 
Expression Analysis of genes encoding GABA signalling components. Analysis of a panel of 32 
inhibitory GABA signalling genes (A- F: GAD1, GAD2, GABAa1, GABAa2, GABAb1, GABAg1) 33 
in control and TSC2 neurons at 60DPP. Data are represented as meansௗ±ௗSEM. *p < 0.05, 34 
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**p < 0.01, ***p < 0.001 following unpaired t-tests, N = 6 for control and 3 for TSC neurons. 1 
Also see Table 1. 2 
 3 
Figure 4 4 
Effects of chronic treatment with rapamycin on TSC2 neuronal activity. Raster (upper panels) 5 
and ASDR plots (lower panels) of a single neuronal MEA culture at 60 DPP in the absence 6 
(A) and presence of rapamycin (10nM) (B). Vertical scale barௗ=ௗ200 spikes per 200ௗms bin. 7 
Underneath show changes in (a) basal excitability, (b) synchronised burst (SB) activity and 8 
the number of spikes in individual SB, (c) SB length and interval and (d) spikes firing outside 9 
of a SB. All plots show meansௗ±ௗSEM. *p < 0.05 following unpaired t-tests. Number of recorded 10 
wells =ௗ6.  11 
 12 
Figure 5 13 
Effects of AICAR and LYN-1604 on TSC2 neuronal activity. (A) Schematic to show the 14 
relationship of TORC1 to AMPK and ULK1. (B) Raster (upper panel) and ASDR (lower panel) 15 
plots of recordings of the same MEA showing 24-hour exposure to AICAR (1 mM) and LYN-16 
1604 (2 ȝM). (C) Gene expression analysis of the genes encoding GABAa2 (a) and GRIA1 17 
(b) in control cells following 24-hour exposure to LYN-1604 (2 ȝM). (D) Network activity 18 
following 24-hour drug treatment of TSC2 neurons  in the absence and presence of AICAR 19 
and LYN-1604 in the absence and presence of AICAR and LYN-1604 showing (a) basal 20 
excitability, (b) synchronised burst (SB) activity and the number of spikes in individual SBs, 21 
(c) SB length and interval  and (d, e) the spikes out of SBs, presented as percentage of the 22 
response before the drugs treatment. (E) Correlation matrices heat map for TSC2 neurons in 23 
the absence and presence of LYN-1604, colours represent the correlation in the firing rates 24 
across the indicated electrode. Correlation matrices are calculated for 16 electrodes in control 25 
and TSC2 neurons plated on the MEAs. Values greater than zero represent positive 26 
correlation, while values below zero represent negative correlation. All plots show 27 
meansௗ±ௗSEM. *p < 0.05, **p < 0.01 following paired t-tests. Number of recorded wells =ௗ7. 28 
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Table 1: Gene expression changes between control and TSC patient neurons 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*S࣯<࣯0.05, **S࣯<࣯0.01, ***S࣯<࣯0.001 (unpaired t-test) 
 
 RNA abundance (mean ± SEM)  
Target gene Control neurons TSC neurons Change 
    
GABAergic cells    
DLX1 0.016 ± 0.009 0.002 ± 0.0004  
DLX2 0.03 ± 0.01 0.05 ± 0.01  
LHX6 0.08 ± 0.02 0.11 ± 0.02  
VGAT 0.03 ± 0.01 0.04 ± 0.01  
    
Synaptic    
PSD95 0.21 ± 0.05 0.12 ± 0.02  
Synaptophysin 0.07 ± 0.01 0.11 ± 0.03  
Homer1 0.37 ± 0.07 0.43 ± 0.05  
    
GABA/Glutamate signalling   
GAD65 0.034 ± 0.02 0.17 ± 0.07*  Ç 
GAD67 0.13 ± 0.07 1.74 ± 0.61** Ç 
*ABAĮ1 0.33 ± 0.05 0.50 ± 0.02   
*ABAĮ2 0.31 ± 0.06 1.14 ± 0.07*** Ç 
GABAȕ1 0.72 ± 0.09 1.59 ± 0.43* Ç 
GABAȖ1 0.062 ± 0.006 0.26 ± 0.03*** Ç 
Grin2a 0.27 ± 0.08 0.14±0.007  
Grin2b 1.35 ± 0.26 0.82 ± 0.06  
Grin3A 0.13 ± 0.036 0.29 ± 0.05* Ç 
GRIN1 0.07 ± 0.007 0.18 ± 0.04** Ç 
GRIA1 1.03 ± 0.14 3.51 ± 1.04* Ç 
Vglut1 0.06 ± 0.009 0.004 ± 0.002** È 
Vglut2 0.1 ± 0.04 3.11 ± 0.85** Ç 
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